Dell Raises 2027 Revenue Forecast as AI Server Demand Drives Record Quarterly Results 
CTOC Goes Live on Bitget Wallet Trading, Expanding Global Access to AI-Powered Healthcare Data Ecosystem 
Kentucky School District Secures $27 Million in Social Media Addiction Lawsuit Settlements 
Morgan Stanley Names Top AI Security and Data Center Stocks for 2026 
PDG Explores $1 Billion Sale of China Data Center Assets 
Samsung Union Dispute Escalates Over Semiconductor Bonus Vote 
Universal Music Group Rejects Pershing Square Takeover Proposal 
Samsung Workers Approve Wage Deal, Avoiding Major Strike and Boosting Chip Supply Confidence 
Salesforce Q1 FY2027 Earnings Beat Expectations Despite Soft Q2 Revenue Outlook 
JPMorgan Sees Biotech Sector at Turning Point, Upgrades Top Pharma Stocks 
Synopsys Q2 FY2026 Earnings Beat Driven by AI and Semiconductor Demand 
US Quantum Stocks Surge After $2 Billion Government Investment 
Autodesk Beats Q1 Estimates, Acquires MaintainX for $3.6 Billion 
Lam Research Expands AI-Powered Semiconductor Tools and Arizona Operations 
HP Q2 2026 Earnings Beat Expectations Despite Memory Chip Pressure 
MongoDB Q1 FY2027 Earnings Beat Expectations, Raises Full-Year Outlook 
European EV Sales Surge in April 2026 as Tesla and Chinese Automakers Gain Ground 
AstraZeneca (NASDAQ:AZN) has announced plans to acquire biotechnology company EsoBiotec for up to $1 billion, aiming to advance its cell therapy capabilities, particularly for cancer and autoimmune treatments. The deal includes an upfront payment of $425 million and up to $575 million in milestone-based payments. Expected to close in Q2 2025, the acquisition will not impact AstraZeneca’s financial guidance for this year.
This move aligns with AstraZeneca’s strategy to strengthen its position in oncology and cell therapy. The pharmaceutical giant has been expanding aggressively, acquiring China-based Gracell Biotechnologies for $1.2 billion in December 2023 and investing $300 million in Maryland for cell therapy research earlier this year.
CEO Pascal Soriot emphasized that emerging technologies, such as antibody-drug conjugates (ADC) and cell therapy, are becoming key components of AstraZeneca’s drug pipeline. EsoBiotec’s cutting-edge platform enables the genetic modification of immune cells directly inside the body, significantly reducing treatment time from weeks to minutes.
By integrating EsoBiotec’s breakthrough technology, AstraZeneca aims to accelerate the development of next-generation therapies, enhancing its position in the competitive biotech landscape. As the demand for innovative cancer treatments rises, this acquisition reinforces AstraZeneca’s commitment to pioneering advancements in precision medicine and immunotherapy.
